BioMarin Pharmaceutical Inc. (BM8.F)
| Previous close | 74.76 |
| Open | 74.62 |
| Bid | 74.92 x 2300 |
| Ask | 74.96 x 2200 |
| Day's range | 74.62 - 74.62 |
| 52-week range | 68.26 - 90.52 |
| Volume | |
| Avg. volume | 12 |
| Market cap | 14.306B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 76.14 |
| EPS (TTM) | 0.98 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 110.83 |
Insider MonkeyHere’s Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN)
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) appreciated 10.17% outperforming the Russell 1000 Value Index’s 8.99%. Stock selection in the Information Technology and Communication Services sectors was the main […]
Simply Wall St.BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 41% Below Their Intrinsic Value Estimate
Key Insights BioMarin Pharmaceutical's estimated fair value is US$142 based on 2 Stage Free Cash Flow to Equity Current...
- Insider Monkey
Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback?
Scout Investments, Inc, an affiliate of Carillon Tower Advisers, released the “Carillon Scout Mid Cap Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. In the first quarter, most indices generated significant gains driven by more cyclical industries including energy, financials, and industrials. The combination of a positive outlook for […]
